Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program partnership. | Pfizer and Flagship Pioneering are turning to autoimmune ...

Pfizer and Flagship will engage Charles River Laboratories to leverage Logica, an artificial intelligence (AI)-powered platform offering from Flagship-founded Valo Health ... “Through the power of our ...

Collaboration leverages Logica, a platform offering from Valo Health and Charles ... signed under strategic partnership between Flagship Pioneering and Pfizer to accelerate discovery of ...

One of the most promising aspects of AI and its integration into the pharmaceutical industry is the technology’s potential to ...

Pfizer (PFE) and Pioneering Medicines, Flagship Pioneering’s in-house drug discovery and development unit, announced an agreement to discover ...

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic diseases, leveraging AI and extensive human datasets.

Novo Nordisk gets a license to three preclinical-stage cardiovascular disease programmes from Valo Health in return for its initial investment and is prepared to expand the partnership to cover 11 ...

Novo Nordisk expanded a deal with Valo Health to discover and develop treatments ... and we believe this partnership will help Novo Nordisk fulfill our ambition to expand the number of new drug ...

Valo Health, Inc. (“Valo”), a biotechnology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence (AI), today ...

Logica, the result of a strategic partnership between Charles River and Valo Health, is the industry’s first computation-powered, unified target-to-candidate offering. Logica leverages the ...